Sutro Biopharma, Inc.
STRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $10 | $64 | $17 | $15 |
| % Growth | -84.8% | 266.4% | 17.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $10 | $64 | $17 | $15 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $40 | $38 | $52 | $71 |
| G&A Expenses | $9 | $10 | $13 | $9 |
| SG&A Expenses | $9 | $10 | $13 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10 | $18 | $21 | $0 |
| Operating Expenses | $58 | $67 | $86 | $80 |
| Operating Income | -$48 | -$3 | -$69 | -$65 |
| % Margin | -499.9% | -5.2% | -393.8% | -440.7% |
| Other Income/Exp. Net | -$8 | -$8 | -$7 | -$5 |
| Pre-Tax Income | -$57 | -$12 | -$76 | -$70 |
| Tax Expense | $0 | -$0 | $0 | $2 |
| Net Income | -$57 | -$11 | -$76 | -$72 |
| % Margin | -586.6% | -18% | -436.6% | -489.2% |
| EPS | -6.7 | -1.4 | -9.1 | -8.8 |
| % Growth | -378.6% | 84.6% | -3.4% | – |
| EPS Diluted | -6.7 | -1.4 | -9.1 | -8.8 |
| Weighted Avg Shares Out | 8 | 8 | 8 | 8 |
| Weighted Avg Shares Out Dil | 8 | 8 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $3 | $4 |
| Interest Expense | $10 | $10 | $11 | $9 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$45 | $1 | -$46 | -$60 |
| % Margin | -459.6% | 1.7% | -261.9% | -402% |